Viridian Therapeutics Investor Relations Material

Viridian Therapeutics Inc. is a biotechnology company focused on developing treatments for patients with serious diseases, particularly those related to rare and underserved conditions. The company’s primary area of research includes therapies for thyroid eye disease (TED) and other autoimmune and inflammatory diseases. Viridian Therapeutics employs innovative biologics and small-molecule technologies to address unmet medical needs and improve patient outcomes through targeted therapeutic approaches. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.